Navigation Links
Fenwal Receives FDA Clearance for Wireless Data Export on ALYX Blood-Collection System
Date:12/16/2010

LAKE ZURICH, Ill., Dec. 16, 2010 /PRNewswire/ -- Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market its ALYX™ component collection system with new wireless data export capabilities.

The ALYX system is a mobile blood component collection device used primarily to collect red blood cells.  The system can collect two units of red cells from a single donor in less than 30 minutes.  

The addition of wireless data export allows blood collection professionals to electronically access detailed information about donation procedures on mobile and fixed-site blood drives.  These data can then be used to track and improve blood center performance and enhance the donation experience for donors and collectors.

When accompanied by the Fenwal data exchange system, scheduled for release in the first half of 2011, data export will allow centers to create customized reports with procedure and other data from the ALYX system.  Blood centers can use these data to identify training opportunities designed to enhance operator and system performance.

Fenwal is unique in offering data export capabilities designed for open-source compatibility with blood and plasma center information systems.  Earlier this year Fenwal received FDA clearance for wireless data export on the Fenwal AMICUS™ system, which is used to collect platelets, and the Fenwal AUTOPHERESIS-C™ system, which collects plasma.  

"In providing data export for apheresis systems, our objective is to help the professionals who collect blood and plasma to improve how they work, optimizing their productivity and offering a positive experience for donors," said William H. Cork, chief technology officer for Fenwal.  "Blood collectors are vital to the nation's blood supply and Fenwal is dedicated to supporting their mission.  Since ALYX is a mobile collection system used in many different settings outside blood centers, wireless capability is helpful to transmit information about mobile collection, allowing centers to gain new insight into their efficiency on mobile blood drives."  

About Fenwal

Fenwal, Inc. (www.fenwalinc.com) is a global medical technology company focused on improving blood collection, filtration, separation, storage and transfusion to ensure the availability, safety and effectiveness of blood components.  Fenwal is unique in the depth of its experience and commitment to transfusion medicine.  The company offers the broadest range of products for the automated and manual collection of blood and blood components.  Fenwal became an independent company in 2007, but its roots go back to 1949 with the founding of Fenwal Laboratories.  Fenwal developed the first flexible, single-use container for blood collection, eliminating complications associated with glass containers and allowing blood to be separated into therapeutic components.  Today, the company's products and advanced collection and separation technologies are used to help treat patients on six continents.  Fenwal, Inc. is based in Lake Zurich, Illinois.


'/>"/>
SOURCE Fenwal, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. William Cork Joins Fenwal as Chief Technology Officer
2. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
3. Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets
4. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
5. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
6. Appellate Court Decides in Favor of Fenwal
7. FDA Clears Software Upgrade for Fenwal Plasma-Collection System
8. Fenwal Named Exclusive Provider of AccuVeins Award-Winning Vein Illumination Device for Blood and Plasma Centers
9. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
10. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. ... and markets innovative proprietary products for the urology market, ... fiscal year ended December 31, 2016 before the market ... The Company will host a conference call and webcast ... Thursday, March 9, 2017 at 11:00 a.m. Eastern Time ...
(Date:2/23/2017)... Feb 23, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Menopause market? ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price ... in the global Fibromyalgia market. The research answers the ... marketed for Fibromyalgia and their clinical attributes? How are they positioned ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... , media relations, content marketing, social media management, corporate communications, SEO and cause ... the state and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus ...
(Date:2/23/2017)... Colorado (PRWEB) , ... February 23, 2017 , ... ... Magazine, an exciting, new, interactive publication where generations converge and explore the world ... expand their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... new partnership with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) ... for children with autism spectrum disorder (ASD) to see films in an environment ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... York (PRWEB) , ... February 22, 2017 , ... ... entrance and lobby of a new healthcare contact center in Georgia, PENETRON Specialty ... One of the nation’s largest healthcare systems recently invested $51 million to purchase ...
Breaking Medicine News(10 mins):